sitocabnagene loxiveleucel
sitocabnagene loxiveleucel: 2 clinical trials tracked.
sitocabnagene loxiveleucel evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
What is verified about sitocabnagene loxiveleucel, and what remains unknown?
Traceable citations · Unknowns marked
Clinical Trial Registry Records (2)
A Phase 1b, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-007, an Allogeneic Anti-CD19 Chimeric Antigen Receptor Natural Killer Cell (CD19 CAR-NK) Therapy, in Adult Subjects With Refractory Lupus Nephritis or Refractory Systemic Sclerosis
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs)